Eris Lifesciences Limited will host a one-on-one virtual meeting with Tokio Marine Asset Management Co. Ltd. on Monday, Aug 17, 2026, at 12:00 PM IST. The interaction aims to update institutional investors on the company’s business performance and strategic outlook using only publicly available information. This disclosure ensures transparency in investor relations while adhering to regulatory standards regarding unpublished price-sensitive information.

The meeting was disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Management representative Krishnakumar Vaidyanathan will lead the discussion on behalf of the company. The schedule is indicative and remains subject to change due to unforeseen developments.

Meeting Details

The company emphasized that no unpublished price-sensitive information (UPSII) will be discussed during the session. All references made by management will be drawn from publicly available documents. Milind Talegaonkar, Company Secretary & Compliance Officer, signed the intimation submitted to BSE Limited and National Stock Exchange of India Limited.

Regulatory Compliance

This disclosure aligns with SEBI’s mandate for listed entities to report interactions with analysts and institutional investors. The requirement prevents selective disclosure of material information, ensuring all shareholders have equal access to significant updates. Eris Lifesciences continues its routine engagement with key financial institutions to maintain market confidence and liquidity.

Eris Lifesciences has drawn down a working capital term loan of ₹64.40 crore from Axis Bank Limited to meet other short-term liabilities, as disclosed in an intimation filed with stock exchanges on August 6, 2026. The company confirmed that this drawdown does not alter its aggregate debt level, indicating a restructuring or rollover of existing obligations rather than new leverage accumulation.

The transaction was executed under a sanction letter dated August 5, 2026. Axis Bank Limited will hold a second charge on assets, including both primary and collateral assets, which are already created for the company’s existing working capital credit facilities. This security arrangement ensures that the new facility is secured against the same asset base as prior borrowings.

Loan Structure and Security Details

The agreement outlines specific terms regarding the nature of the loan and the security provided. The total outstanding amounts for various loan categories were disclosed alongside the new drawdown.

Regulatory Compliance

The disclosure was made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR, 2015). The filing also references Para B of Part A of Schedule III and SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Milind Talegaonkar, Company Secretary & Compliance Officer of Eris Lifesciences, signed the intimation. The company reported no shareholding by Axis Bank in the entity, nor any related-party transaction status for this agreement. No special rights, such as director appointments or subscription rights, were granted to the lender.